Showing 1 - 11 results of 11 for search '"B7-H1 Antigen/antagonists & inhibitors"', query time: 0.92s Refine Results
1
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA):an open-label, multicentre, phase 1/2, basket study

Authors: Saiama N. Waqar, Ding Wang, Haiyan Gao, Sakshi Gulati, Emma V. Jones, Iwanka Kozarewa, Matthew G Krebs, Helen K. Angell, Jean Pierre Delord, Sophie Postel-Vinay, Joon Rhee, Vidalba Rocher-Ros, Antoine Italiano, Susan M. Domchek, Zhongwu Lai, Benoit You, Anna M. L. Coenen-Stass, Sara Bastian, Bella Kaufman, P. Herbolsheimer, Jérôme Alexandre, Yeon Hee Park, Seock-Ah Im, L Opincar, M. Lanasa

Source: Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7

Subject Terms: Adolescent, Adult, Aged, Antibodies, Monoclonal/administration & dosage, B7-H1 Antigen/antagonists & inhibitors, BRCA1 Protein/genetics, BRCA2 Protein/genetics, Breast Neoplasms/drug therapy, Female, Germ-Line Mutation/genetics, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local/drug therapy, Phthalazines/administration & dosage, Piperazines/administration & dosage, Young Adult, Oncology, Metastatic breast cancer, medicine.disease, medicine, Olaparib, chemistry.chemical_compound, chemistry, Lung cancer, Durvalumab, Breast cancer, Internal medicine, medicine.medical_specialty, Adverse effect, business.industry, business, Tolerability, Clinical trial

File Description: application/vnd.openxmlformats-officedocument.wordprocessingml.document

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c34416fb3adf2a299c05113cf960a2c
https://www.research.manchester.ac.uk/portal/en/publications/olaparib-and-durvalumab-in-patients-with-germline-brcamutated-metastatic-breast-cancer-mediola(5e0b81c7-c58f-4a44-98f4-47d6ec2731f4).html

2
‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

Authors: Rotman, J., Mom, C. H., Jordanova, E. S., de Gruijl, T. D., Kenter, G. G.

Contributors: Obstetrics and Gynaecology, CCA - Treatment and quality of life, Obstetrics and gynaecology, Medical oncology laboratory

Source: BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Cancer
BMC cancer, 18(1):888. BioMed Central
BMC Cancer, 18(1). BioMed Central

Subject Terms: Immunotherapy, Cervical cancer, Durvalumab, Programmed cell death ligand 1, Checkpoint inhibitor, Local therapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Study Protocol, Intratumoural, Cancer Research, Genetics, Oncology, Immune system, medicine.medical_treatment, medicine, Antibody, biology.protein, biology, business.industry, business, medicine.disease, Lymph, Lymph node, medicine.anatomical_structure, Surgical oncology, Cancer research, Antibodies, Monoclonal/administration & dosage, Antineoplastic Agents, Immunological/administration & dosage, B7-H1 Antigen/antagonists & inhibitors, Clinical Protocols, Female, Humans, Injections, Intralesional, Lymphatic Metastasis, Molecular Targeted Therapy, Neoplasm Staging, Tumor Microenvironment/drug effects, Uterine Cervical Neoplasms/drug therapy

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9825bbd42f8239d691fa0e30c049d4e1
http://link.springer.com/article/10.1186/s12885-018-4764-0

HTML Full Text     PDF Full Text
3
Hypophysites induites par les immunothérapies anti-néoplasiques

Authors: Payrat, J. A., Cugnet-Anceau, C., Maillet, D., Levy, M., Raverot, G., Disse, E., Borson-Chazot, F.

Contributors: Fédération d'Endocrinologie, Hospices Civils de Lyon (HCL), Institut de Cancérologie [Hospices civils de Lyon], Département Endocrinologie-Diabétologie-Maladies Nutritionnelles [Lyon-Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)

Source: Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2020, 107 (4), pp.490--498. ⟨10.1016/j.bulcan.2020.01.012⟩

Subject Terms: Humans, Risk Factors, Magnetic Resonance Imaging, Immunotherapy, Immunotherapy/*adverse effects, Neoplasms/*therapy, Immunothérapie, ACTH deficiency, Adrenal Cortex Hormones/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, Checkpoint inhibiteurs, Checkpoint inhibitors, CTLA-4 Antigen/antagonists & inhibitors, Déficit corticotrope, Hyponatremia/etiology, Hypophysite, Hypophysitis, Hypophysitis/diagnostic imaging/drug therapy/*etiology, Programmed Cell Death 1 Receptor/antagonists & inhibitors, [SDV]Life Sciences [q-bio]

Access URL: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c755b625267d6571ddf1c31486bf1a5a
https://hal.archives-ouvertes.fr/hal-02901888

4
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

Authors: Cristina, Valerie, Herrera-Gómez, Ruth Gabriela, Szturz, Petr, Espeli, Vittoria, Siano, Marco

Source: International journal of molecular sciences, vol. 20, no. 21
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 20, Iss 21, p 5399 (2019)

Subject Terms: Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, Drug Resistance, Neoplasm, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/immunology, Humans, Immunotherapy, Neoplasm Recurrence, Local, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Squamous Cell Carcinoma of Head and Neck/drug therapy, Squamous Cell Carcinoma of Head and Neck/immunology, Treatment Outcome, combination treatment, head and neck cancer, immunotherapy, Review, lcsh:Biology (General), lcsh:QH301-705.5, lcsh:Chemistry, lcsh:QD1-999, Inorganic Chemistry, Organic Chemistry, Physical and Theoretical Chemistry, Computer Science Applications, Spectroscopy, Molecular Biology, General Medicine, Catalysis, Head and neck squamous-cell carcinoma, medicine.disease, medicine, Head and neck cancer, Chemotherapy, medicine.medical_treatment, Response rate (survey), Oncology, medicine.medical_specialty, Internal medicine, Cetuximab, medicine.drug, Immune Targeting, business.industry, business, Immune checkpoint inhibitors

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a129ec37102cee4c7414e923e44223c
https://serval.unil.ch/resource/serval:BIB_D6D634194460.P001/REF.pdf

5
Very low expression of PD-L1 in medullary thyroid carcinoma

Authors: Caterina Rebecchini, Laurence de Leval, Massimo Bongiovanni, Chiara Saglietti, Gerasimos P. Sykiotis, Laura Marino, Jean-Luc Bulliard

Source: Endocrine-Related Cancer
Endocrine-related cancer, vol. 24, no. 6, pp. L35-L38

Subject Terms: Research Letter, Cancer Research, Endocrinology, Oncology, Endocrinology, Diabetes and Metabolism, B7-H1 Antigen, Immunotherapy, medicine.medical_treatment, medicine, business.industry, business, Thyroid carcinoma, Cancer research, Medullary cavity, PD-L1, biology.protein, biology, Carcinoma, medicine.disease, Neuroendocrine therapy, Adult, Aged, B7-H1 Antigen/antagonists & inhibitors, B7-H1 Antigen/biosynthesis, B7-H1 Antigen/immunology, Carcinoma, Neuroendocrine/immunology, Carcinoma, Neuroendocrine/metabolism, Carcinoma, Neuroendocrine/pathology, Carcinoma, Neuroendocrine/therapy, Female, Humans, Male, Middle Aged, Thyroid Neoplasms/immunology, Thyroid Neoplasms/metabolism, Thyroid Neoplasms/pathology, Thyroid Neoplasms/therapy

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2c64599eee12ccde8e1fbd794a5705
http://europepmc.org/articles/PMC5457503

6
The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors

Authors: Marchand, Lucien, Disse, Emmanuel, Dalle, Stéphane, Reffet, Sophie, Vouillarmet, Julien, Fabien, Nicole, Thivolet, Charles, Cugnet-Anceau, Christine

Contributors: Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier Saint-Joseph Saint-Luc, Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA)

Source: Acta diabetologica
Acta diabetologica, 2019, 56 (12), pp.1239--1245. ⟨10.1007/s00592-019-01402-w⟩

Subject Terms: Humans, Anti-PD-1, Anti-PD-L1, Autoimmune diabetes, Exocrine pancreatic function, Fulminant diabetes, Immunotherapy, Immunotherapy/*adverse effects, Pancreas volume, Immune checkpoint inhibitors side effects, Cell Cycle Checkpoints/drug effects/immunology, Alpha cell pancreatic function, Autoimmune Diseases/chemically induced/epidemiology/etiology, Autoimmune generalised lipoatrophy, Autoimmune lipodystrophy, Autoimmune pancreatitis, B7-H1 Antigen/antagonists & inhibitors/immunology, Beta cell pancreatic function, CTLA-4 Antigen/antagonists & inhibitors/immunology, Diabetes Mellitus, Lipoatrophic/chemically induced/epidemiology/immunology, Type 1/chemically induced/complications/diagnosis/epidemiology, Type 2/*chemically induced/diagnosis/epidemiology/immunology, Programmed cell death-1 (PD-1), Programmed death ligand 1 (PD-L1), Protein Kinase Inhibitors/*adverse effects/therapeutic use, [SDV]Life Sciences [q-bio], Endocrinology, General Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine, Fulminant, Etiology, Medicine, business.industry, business, Bioinformatics, medicine.medical_treatment, Lipoatrophy, medicine.disease, Type 2 diabetes, Decompensation, Diabetes mellitus

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30cf7580fcdfdce130547728c6f643f8
https://hal.archives-ouvertes.fr/hal-02465748

7
Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype

Authors: Marchand, Lucien, Thivolet, Arnaud, Dalle, Stéphane, Chikh, Karim, Reffet, Sophie, Vouillarmet, Julien, Fabien, Nicole, Cugnet-Anceau, Christine, Thivolet, Charles

Contributors: Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)

Source: Acta Diabetol
Acta Diabetol, 2019, 56 (4), pp.441--448. ⟨10.1007/s00592-018-1234-8⟩

Subject Terms: Immunotherapy, Immune checkpoint inhibitors side-effects, Aged, 80 and over, Alpha-cell pancreatic function, Anti-PD-1, Anti-PD-L1, Antibodies, Monoclonal, Humanized/adverse effects, Monoclonal/adverse effects, Autoantibodies/blood, Autoimmune diabetes, B7-H1 Antigen/antagonists & inhibitors/*immunology, Beta-cell pancreatic function, Diabetes mellitus, Diabetes Mellitus/*chemically induced/pathology, Exocrine pancreatic function, Female, Fulminant diabetes, Humans, Immunotherapy/*adverse effects, Islets of Langerhans/*drug effects/metabolism/pathology, Male, Middle Aged, Mixed meal test, Nivolumab/adverse effects, Pancreas volume, Pancreas, Exocrine/*drug effects/metabolism/pathology, Phenotype, Programmed Cell Death 1 Receptor/antagonists & inhibitors/*immunology, Programmed cell death-1, Programmed death ligand 1, [SDV]Life Sciences [q-bio], Endocrinology, General Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine, Internal medicine, medicine.medical_specialty, medicine, business.industry, business, Ketoacidosis, medicine.disease, Type 1 diabetes, medicine.anatomical_structure, Nivolumab, Endocrine system, Durvalumab, Gastroenterology, Pembrolizumab

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113b7ed78d7f74086f683082d650dfb4
https://hal.archives-ouvertes.fr/hal-02195223

8
Survival of the fittest: Cancer challenges T cell metabolism

Authors: Franchina, Davide G, He, Feng, Brenner, Dirk

Source: Franchina, D G, He, F & Brenner, D 2018, ' Survival of the fittest : Cancer challenges T cell metabolism ', Cancer Letters, vol. 412, pp. 216-223 . https://doi.org/10.1016/j.canlet.2017.10.014

Subject Terms: Cancer Research, Oncology, Immunosurveillance, Stromal cell, Biology, Cancer cell, Cell biology, Tumor microenvironment, Tumor-infiltrating lymphocytes, Cell metabolism, Immune system, T cell, medicine.anatomical_structure, medicine, Journal Article, Anti-tumor response, Metabolic reprogramming, Metabolism, Reactive Oxygen Species/metabolism, Tumor Escape, Humans, Programmed Cell Death 1 Receptor/physiology, Energy Metabolism, B7-H1 Antigen/antagonists & inhibitors, Immunotherapy, Glycolysis, Neoplasms/immunology, T-Lymphocytes/metabolism

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb6379879d3ed2c8ef98af77cf17d53

9
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Authors: Antonia, Scott J., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki H., de Wit, Maike, Cho, Byoung C., BOURHABA, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S., Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E., Paz-Ares, Luis, de Castro Carpeno, Javier, Wadsworth, Catherine, Melillo, Giovanni, Jiang, Haiyi, Huang, Yifan, Dennis, Phillip A., Ozguroglu, Mustafa

Source: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377(20), 1919-1929., United States. (2017).

Subject Terms: Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal/adverse effects/therapeutic use, Antineoplastic Agents/adverse effects/therapeutic use, B7-H1 Antigen/antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung/mortality/secondary/therapy, Chemoradiotherapy, Disease-Free Survival, Female, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Lung Neoplasms/mortality/pathology/therapy, Male, Middle Aged, Neoplasm Staging, Oncology [Human health sciences], Oncologie [Sciences de la santé humaine], Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

Access URL: https://explore.openaire.eu/search/publication?articleId=od______1318::139eb39c33091a4c1004d8edbdea7957
https://orbi.uliege.be/handle/2268/222538

10
Electronic Resource
Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition:impact on clinical outcome

Source: Araujo B de Lima , V , Borch , A , Hansen , M , Draghi , A , Spanggaard , I , Rohrberg , K , Reker Hadrup , S , Lassen , U & Svane , I M 2020 , ' Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition : impact on clinical outcome ' , Cytotherapy , vol. 22 , no. 4 , pp. 204-213 .

Index Terms: Adult, Aged, B7-H1 Antigen/antagonists & inhibitors, Biopsy, CD8-Positive T-Lymphocytes/immunology, Female, Follow-Up Studies, Humans, Immunologic Factors/pharmacology, Immunotherapy/methods, Lymphocytes, Tumor-Infiltrating/drug effects, Male, Middle Aged, Molecular Targeted Therapy/methods, Neoplasms/pathology, Phenotype, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Treatment Outcome, Tumor Microenvironment/drug effects, article

11
Electronic Resource
Cancer immunotherapy in patients with preexisting autoimmune disorders

Source: Donia , M , Pedersen , M & Svane , I M 2017 , ' Cancer immunotherapy in patients with preexisting autoimmune disorders ' , Seminars in Immunopathology , vol. 39 , no. 3 , pp. 333-337 .

Index Terms: Antibodies, Monoclonal/adverse effects, Antineoplastic Agents/adverse effects, Autoimmune Diseases/complications, B7-H1 Antigen/antagonists & inhibitors, CTLA-4 Antigen/antagonists & inhibitors, Humans, Immune Tolerance, Immunosuppression, Immunotherapy/adverse effects, Molecular Targeted Therapy/adverse effects, Neoplasms/complications, Neoplasms, Second Primary/etiology, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Risk, Treatment Outcome, article

Search Tools: Get RSS Feed — Email this Search